Search research articles
Contact Us
Filters
Showing results (161-170 of 184) with videos related to
Page
of 19
Sort By:
Blood Cancer Journal
|
April 12, 2026
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma
Hamza Hashmi, Tara Sebastian, Sridevi Rajeeve, et al.
Blood Cancer Journal
|
May 31, 2024
Comparison of infectious complications with BCMA-directed therapies in multiple myeloma
Karthik Nath, Tala Shekarkhand, David Nemirovsky, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 26, 2026
Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies
Issam S Hamadeh, Maximillian Merz, Andriy Derkach, et al.
Blood
|
July 7, 2026
Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma
Sham Mailankody, Sneha Mitra, Kevin Herrera, et al.
Blood Advances
|
May 2, 2025
Outcomes in Frail Patients Receiving BCMA-directed Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma
Benjamin O Adegbite, Carlyn Rose Tan, Tala Shekarkhand, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 28, 2021
Initial Whole-Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001
Francesco Maura, Benjamin Diamond, Kylee H Maclachlan, et al.
Blood Advances
|
February 17, 2026
IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM
Kylee H Maclachlan, Carlyn Rose Tan, Tala Shekarkhand, et al.
Blood Advances
|
October 25, 2023
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma
Ross S Firestone, Devin McAvoy, Tala Shekarkhand, et al.
Blood
|
April 8, 2025
Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis
Surbhi Sidana, Nausheen Ahmed, Othman Salim Akhtar, et al.
The Lancet. Haematology
|
May 28, 2021
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial
Benjamin Diamond, Neha Korde, Alexander M Lesokhin, et al.
Page
of 19
Search research articles
Search
Showing results (161-170 of 184) with videos related to
Sort By:
Page
of 19
Blood Cancer Journal
|
April 12, 2026
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma
Hamza Hashmi, Tara Sebastian, Sridevi Rajeeve, et al.
Blood Cancer Journal
|
May 31, 2024
Comparison of infectious complications with BCMA-directed therapies in multiple myeloma
Karthik Nath, Tala Shekarkhand, David Nemirovsky, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 26, 2026
Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies
Issam S Hamadeh, Maximillian Merz, Andriy Derkach, et al.
Blood
|
July 7, 2026
Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma
Sham Mailankody, Sneha Mitra, Kevin Herrera, et al.
Blood Advances
|
May 2, 2025
Outcomes in Frail Patients Receiving BCMA-directed Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma
Benjamin O Adegbite, Carlyn Rose Tan, Tala Shekarkhand, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 28, 2021
Initial Whole-Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001
Francesco Maura, Benjamin Diamond, Kylee H Maclachlan, et al.
Blood Advances
|
February 17, 2026
IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM
Kylee H Maclachlan, Carlyn Rose Tan, Tala Shekarkhand, et al.
Blood Advances
|
October 25, 2023
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma
Ross S Firestone, Devin McAvoy, Tala Shekarkhand, et al.
Blood
|
April 8, 2025
Standard-of-Care Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis
Surbhi Sidana, Nausheen Ahmed, Othman Salim Akhtar, et al.
The Lancet. Haematology
|
May 28, 2021
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial
Benjamin Diamond, Neha Korde, Alexander M Lesokhin, et al.
Page
of 19